The Drug Pipeline: Beyond the Familiar Names
The biggest story in the past year has been the arrival of orforglipron, sold under the brand name Foundayo. Approved by regulators in April 2026, it is the first oral non-peptide GLP-1 receptor agonist that does not require fasting or injection. The ATTAIN trials, which enrolled over 4,500 participants globally, showed that people on the highest dose lost an average of 12.4% of their body weight over 72 weeks. Nearly 60% of participants dropped at least 10% of their starting weight. Because it is a pill rather than an injection, it has drawn attention from people who find needles unappealing or who travel frequently.
But the pipeline does not stop there. Pfizer is currently recruiting for its berobenatide trial, studying a compound known as PF-08653944 in people with overweight or obesity. Roche has a dual GLP-1/GIP receptor agonist called enicepatide in development, with trials aimed at participants who also have type 2 diabetes. Novo Nordisk continues testing next-generation compounds, including NNC0662-0419, with trial sites in Arizona and other states. Meanwhile, a drug called CBL-514 is being studied specifically to address a problem that has frustrated many GLP-1 users: weight regain after stopping medication. The Phase 2 trial combines CBL-514 with tirzepatide and then tracks what happens to abdominal fat once both drugs are discontinued.
The head-to-head data is also worth noting. The SURMOUNT-5 trial, published in 2025, compared tirzepatide and semaglutide directly in 751 adults without diabetes. At 72 weeks, tirzepatide produced a mean weight loss of 20.2% compared to 13.7% for semaglutide. A real-world Mayo Clinic study of 511 patients found similar results: 16.6% loss with tirzepatide versus 13.4% with semaglutide at 12 months.
Behavioral and Lifestyle Trials: The Other Half of the Picture
Not every trial involves a new pharmaceutical. A substantial number of studies are testing whether structured programs, digital tools, or coaching models can produce lasting results. The Mayo Clinic is running a prospective study evaluating its branded diet program against usual care, measuring outcomes at 24 and 52 weeks—including body composition and quality of life, not just the number on the scale.
San Diego State University has been recruiting for a trial that examines whether mobile health apps can improve outcomes in people with overweight and obesity. Participants commit to six months of daily app use, morning weigh-ins, and fasting blood glucose checks. Cedars-Sinai in Los Angeles has tested two different self-regulation strategies: one focused on environmental control (removing tempting foods from the home) and another on impulse control training (building the mental muscle to resist cravings). These kinds of studies often appeal to people who prefer a non-pharmaceutical approach or who want to understand the behavioral science behind their eating patterns.
The Department of Veterans Affairs has also contributed meaningful data through its Coach to Fit program, which studied weight loss interventions for veterans with serious mental illness. Results posted in 2026 showed measurable improvements in body weight and BMI at six months, with some participants achieving 7% total weight loss.
What Joining a Trial Actually Looks Like
Most people have questions about the practical side of enrollment. Here is what the process typically involves.
Screening comes first. You will go through a series of baseline assessments that may include blood work, an electrocardiogram, body measurements, and a medical history review. Trials have specific inclusion criteria. The most common one is BMI—many drug trials require a BMI of 30 or higher, or 27 and above with at least one weight-related condition like hypertension. Some studies also require that your weight has been stable for the previous three months and that you have not used GLP-1 medications within a 90-day window before screening.
The time commitment varies enormously. A short Phase 1 study might involve a few overnight stays and periodic follow-up visits. Longer Phase 3 trials can run for 72 weeks or more, with regular check-ins every few weeks. Behavioral studies often require daily engagement—logging meals, wearing activity monitors, or using an app—but fewer in-person visits.
Compensation is not guaranteed, but many trials do offer it. The amount depends on the study phase, the burden on participants, and the sponsoring institution. Some trials reimburse for travel and time. Others provide the study medication and related care at no cost to participants. The financial details are always disclosed during the informed consent process, and you should ask about them directly before enrolling.
Location matters more than you might think. Trials cluster around major research centers. Phoenix, San Antonio, Chicago, and Houston currently have the highest concentration of actively recruiting obesity studies. If you live outside these areas, you may need to consider whether travel is feasible. Some trials offer remote components, but most drug studies require in-person visits for safety monitoring.
Types of Fat Loss Trials: A Comparison
| Trial Type | What Is Tested | Typical Duration | Who It Suits | Key Considerations |
|---|
| Phase 1 Drug Trial | New compound, first in humans | Weeks to months | Healthy volunteers willing to accept uncertainty | Small participant groups; focused on safety, not efficacy |
| Phase 2/3 Drug Trial | Established drug class, dose-finding | 6-18 months | People with BMI ≥30 or ≥27 with comorbidities | Higher chance of receiving active treatment; more sites available |
| Behavioral Intervention | Diet, exercise, coaching programs | 3-12 months | Broad eligibility; often lower BMI thresholds | No medication risk; requires consistent daily engagement |
| Digital Health Study | Apps, wearables, telehealth coaching | 3-6 months | Tech-comfortable individuals | Often remote-friendly; lower compensation typical |
| Combination Trial | Drug plus lifestyle or two drugs | 12-18 months | Those who want comprehensive approach | More demanding schedule; richer data collection |
How to Find Trials and What to Ask
The most direct route is ClinicalTrials.gov, a database maintained by the National Library of Medicine. You can search by condition ("obesity" or "overweight"), filter by location, and see which studies are actively recruiting. The NIH also runs trials through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which occasionally seeks participants for metabolic research at its Bethesda campus.
Major academic medical centers—Mayo Clinic, Cedars-Sinai, the University of Pittsburgh, and others—maintain their own trial listings. Pharmaceutical companies like Eli Lilly, Novo Nordisk, and Pfizer also post recruitment information on their websites and through third-party platforms.
When you contact a study coordinator, there are several questions worth asking up front: What is the total time commitment over the full study period? Are there any costs I should expect, such as travel or parking? What happens after the trial ends—is there a follow-up period or an extension study? Will I learn which treatment I received? And perhaps most importantly: what are the known side effects of the intervention being tested?
Sarah, a 42-year-old teacher in Texas, joined a behavioral weight loss trial after struggling with post-pregnancy weight that did not respond to commercial programs. "I thought I had tried everything," she said. "The trial gave me access to a registered dietitian and a structured plan that I did not have to pay for. The weekly check-ins kept me accountable in a way that an app never did." She lost 14% of her body weight over the 12-month study.
Another participant, Michael, a 55-year-old engineer from Arizona, enrolled in a Phase 2 drug trial after his doctor suggested he look into clinical research. "I was nervous about being a guinea pig," he admitted. "But the screening process was thorough, and I felt like the research team was genuinely watching out for me. The medication worked—I lost about 18% of my body weight—but what surprised me was how much I learned about my own habits through the required food logging."
Making Sense of the Risks
No clinical trial is risk-free. Drug studies carry the possibility of side effects, and with newer compounds, the full safety profile may not be known. GLP-1 based medications commonly cause gastrointestinal issues—nausea, diarrhea, constipation—that range from mild to troublesome. In the ATTAIN trials for orforglipron, gastrointestinal side effects occurred in 44% to 70% of participants, compared to 18% in the placebo group.
Behavioral trials have a different risk profile. The main drawback is usually disappointment: the program may not work as well as hoped, or the time commitment may feel unsustainable. The informed consent document you sign before joining any trial will spell out these details, and you should read it carefully. You can withdraw from a trial at any time for any reason.
One underappreciated aspect of clinical trials is that they provide a level of medical monitoring that most people do not receive in routine care. Regular blood work, body composition scans, and check-ins with research staff can catch issues early. Some participants have told researchers that the monitoring alone felt valuable, even when the intervention itself was modest.
Where to Start
If you are considering a fat loss clinical trial, begin by searching ClinicalTrials.gov with the terms "obesity" or "overweight" and filtering for your state. Major cities with research hospitals will have the most options. Talk to your primary care provider about whether a trial might be appropriate for your health profile. Some physicians can refer you to studies they know about, particularly if they are affiliated with an academic center.
The research community is actively looking for participants who represent the full diversity of the population. Trials often struggle to enroll enough men, enough people from minority backgrounds, and enough older adults. If you fall into one of these categories, your participation may be especially valuable to researchers—and you may have more options than you expect.
The tools for fat loss have never been more varied. Clinical trials are one way to access them while contributing to knowledge that will shape treatment for years to come.
研究の知恵